Kala Pharmaceuticals, based in Waltham, Mich., has received $11.5 million dollars in Series A financing for the development of a gel-based substance designed to treat wet age-related macular degeneration, according to an Xconomy report.
Kala Pharmaceuticals received the funding from Crown Venture Fund, Third Rock Ventures, Lux Capital Management and Polaris Venture.
The macular degeneration treatment is the first to be developed that will not need to be delivered to the eye via injection.
Kala Pharmaceuticals was founded in 2009 by Justin Hanes of Johns Hopkins University in Baltimore, Bob Langer of MIT in Cambridge, Mass., and Colin Gardner formerly of Johnson & Johnson, based in Brunswick, N.J.
More Articles on Ophthalmology:
Dr. Snow Slade Opens Mesquite Ophthalmology in Nevada
Ocular Therapeutix Seeking FDA Approval for ReSure Sealant
TearScience Receives $70M in Funding
Kala Pharmaceuticals received the funding from Crown Venture Fund, Third Rock Ventures, Lux Capital Management and Polaris Venture.
The macular degeneration treatment is the first to be developed that will not need to be delivered to the eye via injection.
Kala Pharmaceuticals was founded in 2009 by Justin Hanes of Johns Hopkins University in Baltimore, Bob Langer of MIT in Cambridge, Mass., and Colin Gardner formerly of Johnson & Johnson, based in Brunswick, N.J.
More Articles on Ophthalmology:
Dr. Snow Slade Opens Mesquite Ophthalmology in Nevada
Ocular Therapeutix Seeking FDA Approval for ReSure Sealant
TearScience Receives $70M in Funding